Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03112083
Other study ID # OP001
Secondary ID
Status Completed
Phase N/A
First received March 27, 2017
Last updated April 7, 2017
Start date October 6, 2015
Est. completion date June 17, 2016

Study information

Verified date April 2017
Source Olympic Seafood AS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.

The study was a randomised, double-blinded, placebo-controlled intervention study with slightly obese subjects with mildly or moderately elevated blood pressure. Study was conducted at two study sites in Central (Tampere) and Northern Finland (Oulu). In total 35 subjects were randomised according to randomisation list to two groups (krill powder or placebo) in a balanced manner (1:1), separately for both gender and site. Concealed allocation was used to keep both subjects and staff blinded. The study consisted of a pre-screening, Day -7-(-14) screening visit, Day 0 baseline (Randomization visit) and 8-week safety and tolerance follow-up period with three follow-up visits on Day 14, Day 28 and Day 56.

As a primary endpoint of the study, the total number of reported adverse events were compared in the study subject groups taking 8 capsules (4 g) krill oil powder or 8 capsules (4 g) of placebo for the 8-week follow-up period.


Description:

Krill powder is a food supplement rich in active ingredients such as fatty acids, phospholipids, protein and antioxidants like astaxanthin. It is considered to be more effective in lowering triglyceride values than fish oils and it may have positive effect on cholesterol values as well. Krill proteins may have positive effect on blood pressure and astaxanthin has anti-oxidative and anti-inflammatory properties. Thus, krill powder has a lot of potential in improving lipid values and having other positive health effects on cardiovascular system. However, there haven't been many clinical studies done with krill powder and thus systematic data on human safety is limited.

The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.

The study was a randomised, double-blinded, placebo-controlled intervention study with slightly obese subjects with mildly or moderately elevated blood pressure. Study was conducted at two study sites in Central (Tampere) and Northern Finland (Oulu). In total 35 subjects were randomised according to randomisation list to two groups (krill powder or placebo) in a balanced manner (1:1), separately for both gender and site. Concealed allocation was used to keep both subjects and staff blinded. The study consisted of a pre-screening, Day -7-(-14) screening visit, Day 0 baseline (Randomization visit) and 8-week safety and tolerance follow-up period with three follow-up visits on Day 14, Day 28 and Day 56.

A total of 6 study visits were included. At pre-screening visit the study subjects were requested to sign pre-screening visit informed consent form. A structured interview on demographics (age, sex, ethnicity), previous and current diseases, current medication, alcohol and tobacco consumption and use of dietary supplements (especially fish oil and other n-3 fatty acid (FA) supplements, plant sterols and cholesterol lowering fiber supplements (guar gum, glucomannan, oat fiber etc.) and use of fish foods was carried out at the screening visit and replicated at the day 56 visit. Study included one test product: krill powder derived from antarctic krill (Euphausia Superba) (Rimfrost Pristine®, Rimfrost AS, PO box 234, 6099 Fosnavaag, Norway) and placebo product and both were given in capsule form, 4 capsules in the morning and 4 in the evening.

Nutritional counselling regarding the consumption of fish, omega-3 and -6 fatty acids, food supplements and investigational product for the duration of the study were given for the study subjects at the screening visit by a study nurse or registered dietitian and compliance was followed throughout the study. The subjects were advised to keep their medication, lifestyle, background diet and body weight constant during the study and deviation were recorded into the diary.

As a primary endpoint of the study, the total number of reported adverse events were compared in the study subject groups taking 8 capsules (4 g) krill oil powder or 8 capsules (4 g) of placebo for the 8-week follow-up period. Any unfavourable and unintended sign, symptom or medical complaint and worsening of a pre-existing condition was regarded as adverse event (AE). Study subjects kept diary for the whole duration of the study and were requested to write down all unfavourable symptoms and medical complaints not existing at baseline or significantly worsened from baseline situation. Completeness of diaries was checked at each study visit. All reported adverse events were recorded, coded and analysed carefully to determine severity, possible relation to study products, onset and outcome of the event. In addition, safety laboratory values, cholesterol and triglyceride values and blood pressure was measured.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date June 17, 2016
Est. primary completion date June 17, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 18-65 years

- Slightly obese female and male subjects (BMI between 25-30 kg/ m2)

- Mildly or moderately elevated blood pressure (RR systolic 130-159/ diastolic under 99)

- Signed written informed consent

Exclusion Criteria:

- Medication potential to affect serum lipids (lipid-lowering drugs)

- Familial hypercholesterolemia, marked combined hyperlipidemia, condition that would impair fat absorption (e.g. chronic pancreatitis, pancreatic lipase deficiency syndrome)

- Any untreated medical condition affecting absorption of fat

- Type 1 and 2 diabetes

- Cancer or other malignant disease within the past five years

- Periodical hormone replacement therapy

- High intake of oily fish (>2 times per week as a principal meal) (i.e. salmon, herring, sardines, mackerel, vendace)

- Smoking

- Alcohol consumption >15 doses per week

- Pregnant, lactating or wish to become pregnant

- Hypersensitivity to fish or any of the components of the test products

- Regular use (> 3 times per week) of n-3 or other fatty acid supplements, plant sterols or fiber supplements 4 weeks before randomization

- Lack of suitability for participation in the trial, for any medical reason, as judged by the PI

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Nutritional counseling A
Krill powder capsules
Nutritional counselling B
Placebo capsules

Locations

Country Name City State
Finland Oy Medfiles Ltd Kuopio

Sponsors (1)

Lead Sponsor Collaborator
Olympic Seafood AS

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Adverse events Total number of reported adverse events Screening, baseline, day 28, day 56
Secondary Type of adverse event Coding by MedDRA and reported with System organ class (SOC) and Prefered term (PT) levels, seriousness, severity, onset and causality of the reported adverse events Screening, baseline, day 28, day 56
Secondary Change in Systolic blood pressure Mean and mean change (0 vs 8 wk) in systolic blood pressure recorded with 1 mmHg accuracy taken in the screening and during the intervention visits (three measurements are taken altogether and an average of last two measures is used in the analysis) Screening, baseline, day 28, day 56
Secondary Change in Diastolic blood pressure Mean and mean change (0 vs 8 wk) in diastolic blood pressure recorded with 1 mmHg accuracy taken in the screening and during the intervention visits (three measurements are taken altogether and an average of last two measures is used in the analysis) Screening, baseline, day 28, day 56
Secondary Change in thyrotropin Regular safety parameters from the blood including mean and median variables of blood thyrotropin Screening, baseline, day 28, day 56
Secondary Change in Alanine transaminase (ALT) Regular safety parameters from the blood including mean and median variables of blood Alanine transaminase (ALAT) Screening, baseline, day 28, day 56
Secondary Change in Aspartate transaminase (AST) Regular safety parameters from the blood including mean and median variables of blood Aspartate transaminase (ASAT) Screening, baseline, day 28, day 56
Secondary Change in blood glucose Regular safety parameters from the blood including mean and median variables of blood glucose Screening, baseline, day 28, day 56
Secondary Change in gamma glutamyl transferase Regular safety parameters from the blood including mean and median variables of gamma glutamyl transferase Screening, baseline, day 28, day 56
Secondary Change in creatinine Regular safety parameters from the blood including mean and median variables of creatinine Screening, baseline, day 28, day 56
Secondary Change in blood count Regular safety parameters from the blood including mean and median variables of blood count Screening, baseline, day 28, day 56
Secondary Change in Thyroid stimulating hormone (TSH) Regular safety parameters from the blood including mean and median variables of Thyroid stimulating hormone (TSH) Screening, baseline, day 28, day 56
Secondary Change in Triglycerides Mean concentration of serum total triglycerides and mean change (0 vs 8 wk) in serum total and lipoprotein lipids Screening, baseline, day 28, day 56
Secondary Change in total cholesterol Mean concentration of total cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids Screening, baseline, day 28, day 56
Secondary Change in Low density lipoproteine (LDL)-cholesterol Mean concentration of serum LDL-cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids Screening, baseline, day 28, day 56
Secondary Change in High density lipoproteine (HDL)-cholesterol Mean concentration of serum HDL-cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids Screening, baseline, day 28, day 56
See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Recruiting NCT05799053 - Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study Phase 3